| KRAS_EGFR | - |
25122437 | non small cell lung cancer;lung cancer |
FISH |
- |
EGFR IHC, EGFR FISH, and EGFR/KRAS mutation status were not predictive of outcome.
|
| KRAS_EGFR | - |
26095438 | non small cell lung cancer;lung cancer;adenocarcinoma |
FISH |
- |
The histologic findings and ALK immunohistochemistry results were reviewed and compared with the results of ALK-FISH and EGFR/KRAS mutation status.
|
| KRAS_EGFR | - |
22071784 | adenocarcinoma |
FISH |
- |
In 2011, the French National Cancer Institute recommended ALK-fluorescence in situ hybridization (FISH) testing in all EGFR/KRAS-negative adenocarcinomas by all the hospital molecular genetics platforms of cancers.
|
| KRAS_EGFR | - |
21062932 | lung cancer;adenocarcinoma |
FISH |
- |
All positive cases were adenocarcinomas, 12 were EGFR/KRAS wild-type, and 1 had a coexistent EGFR exon 20 mutation. /// "Prescreening by histology, EGFR/KRAS mutations, and smoking status dramatically increases the ALK-positive hit rate compared with unselected series.. "
|
| KRAS_EGFR | - |
19855375 | adenocarcinoma |
FISH |
- |
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas..
|
| KRAS_EGFR | - |
20624322 | non small cell lung cancer;lung cancer;adenocarcinoma |
PCR |
- |
The EML4-ALK fusion gene was present at a high frequency in Chinese NSCLC patients, particularly in those with adenocarcinomas lacking EGFR/KRAS mutations. /// "The EML4-ALK fusion was associated with non-smokers (P = 0.03), younger age of onset (P = 0.03), and adenocarcinomas without EGFR/KRAS mutations (P = 0.04). "
|
| KRAS_EGFR | - |
23927885 | adenocarcinoma |
- |
- |
Two series of consecutive TTNB with 18-gauge needles performed before and after the publication of the ATS/ERS/IASLC guidelines, were retrospectively compared regarding their adequacy for histological sub-typing and EGFR/KRAS mutations and ALK rearrangement testing.
|
| KRAS_EGFR | - |
25973127 | squamous cell carcinoma |
- |
- |
After failure to chemotherapy, genotype testing showed wild-type EGFR/KRAS and ALK rearrangement positive.
|
| KRAS_EGFR | - |
23341890 | non small cell lung cancer;lung cancer;adenocarcinoma |
- |
- |
No EGFR/KRAS mutations were detected among the EML4-ALK positive patients.
|
| KRAS_EGFR | - |
25243942 | adenocarcinoma |
- |
- |
Pathologic features such as differentiation, the presence of signet ring cell, EGFR/KRAS mutation status, and TTF-1 expression were also reviewed.
|
| KRAS_EGFR | - |
24300132 | non small cell lung cancer;lung cancer;adenocarcinoma |
ISH |
- |
Of the tumors with available data on the EGFR/KRAS mutation status, EGFR and KRAS mutation rates were 64% (69/108) and 5% (5/102), respectively.
|
| KRAS_EGFR | - |
25582278 | lung cancer;adenocarcinoma |
- |
- |
EGFR/KRAS mutations and EML4-ALK fusions were similar between GGO and solid adenocarcinomas.
|